HAIs Take Center Stage at the AVA Conference 2015
Sciesent was proud to be part of the Association for Vascular Access 2015 conference in Dallas, TX. With the increased concern with HAIs in the medical industry, we focused our presentation around the topic. Lise Moloney, Director of Business Development - Medical, presented the poster to audience. Here is an abstract of the poster:
Healthcare-associated infections (HAIs), many of which are caused by antibiotic resistant bacteria, impact one in 25 patients in the U.S. each year . These preventable infections claim the lives of 75,000 people and cost between $36-$45 billion annually to treat . Due to efforts by the Centers for Disease Control and Prevention (CDC), the dangers of HAIs and antibiotic resistance are well known and progress has been made to combat them.
Between 2008 and 2013, central-line associated bloodstream infection (CLABSI) rates dropped by 46% . Yet despite these reductions in HAIs, the healthcare industry has a long way to go to eliminate them all together, which is a goal that has been set by the US Department of Health and Human Services . And with the growing concern of antibiotic resistant organisms in the healthcare setting, the stakes have never been higher for preventing these infections.
Antimicrobial central venous catheters (CVCs) have been used to further lower CLABSI rates in high-risk populations and when infection rates remain high despite implementation of a comprehensive strategy to reduce CLABSI rates. Antimicrobial CVCs that are effective against antibiotic resistant bacteria could play a role in minimizing exposure and risk to resistant organisms in the healthcare setting.